To Restrict or Not To Restrict That Is The Question? Divided We Stand! Or Undivided We Stand!! By Joseph K. McKane SPE, Art Unit 1626.

Slides:



Advertisements
Similar presentations
First Action Interview Pilot Program Overview. Pilot Program Objectives Promote personal interviews prior to issuance of a first Office action on the.
Advertisements

USPTO Restriction Training Materials and Chapter 800 Revisions
AIPLA PRESENTATION FOR USPTO PUBLIC HEARING ON REEXAMINATION Q. TODD DICKINSON AIPLA EXECUTIVE DIRECTOR JUNE 1,
More on Restriction Practice Jim Housel SPE, Art Unit 1648 (703)
Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting October 8, 2002 William F. Smith Administrative Patent Judge Board of Patent Appeals.
UNITED STATES PATENT AND TRADEMARK OFFICE A full transcript of this presentation can be found under the “Notes” Tab. Claim Interpretation: Broadest Reasonable.
1 Rule 132 Declarations and Unexpected Results Richard E. Schafer Administrative Patent Judge Board of Patent Appeals and Interferences.
Double Patenting Simplified
Joseph K. McKane SPE, Art Unit U.S.C. 112, second paragraph Allows the public to determine exactly what the boundaries of the claimed inventions.
Julie Burke TC1600 QAS REJOINDER PRACTICE Julie Burke TC1600 QAS
1 35 USC 112, 1 st paragraph enablement Enablement Practice in TC 1600 Deborah Reynolds, SPE
September 14, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December.
35 U.S.C. 112, Sixth Paragraph MPEP 2181 – 2186 Jean Witz Quality Assurance Specialist Technology Center 1600.
1 Principles in Restriction Practice TC 1600 Anthony Caputa TC Practice Specialist (571)
Enhanced First Action Interview (EFAI) Pilot Program Wendy Garber Tech Center Director, 2100 United States Patent & Trademark Office.
Accelerated Examination Bennett Celsa (TC 1600: QAS)
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
Restriction Practice for Nucleic Acid Molecules Julie Burke QAS/PM
Restriction Practice for Genus Claims Species Claims Linking Claims and Markush Claims Julie Burke QAS/PM TC1600.
Clarity and Markush Claims
1 REISSUE OVERVIEW 35 USC Filing Requirements 2. Oaths or Declarations 3. Grounds for Filing 4. Consent 5. Limitations 6. Recapture.
By Paul J. Lee. Disclaimer The opinions and views expressed in these materials are not necessarily those of DexCom and reflect only the personal views.
1 Unity of Invention: Biotech Examples TC1600 Special Program Examiner Julie Burke (571)
RESTRICTING BETWEEN PRODUCT and PROCESS INVENTIONS Bruce Campell Supervisory Patent Examiner Art Unit
Current and Future USPTO Practice RESTRICTION PRACTICES AT THE USPTO 1 © AIPLA 2015.
Full First Action Interview (FFAI) Pilot Program Wendy Garber Tech Center Director, 2100 United States Patent & Trademark Office.
Julie Burke TC1600 QAS/PM New Matter, Incorporation By Reference, Restriction and Claim Language for Nucleic Acid Molecules.
2 23,503 hours in FY 2013, compared with 21,273 hours in FY ,651 interview hours in FY 13 have been charged through the AFCP program. Interview.
1 1 Interview Practice Within the USPTO. 2 2 Topics Effective Interviews Reaching Agreement Requesting Interviews Issues Discussed Documenting Interviews.
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
Patent Lawyer's Club of Washington October 24, Michael R. Fleming Chief Administrative Patent Judge Changes.
Notice of Proposed Rule Making Affecting Claims That Recite Alternatives 1 Robert Clarke, Director Office of Patent Legal Administration (571)
1 AIPLA Biotech Committee Meeting Washington D.C., October 14, 2004 Jasemine C. Chambers, Ph.D., J.D. Director Technology Center 1600 USPTO (571)
Restriction & Double Patenting Mojdeh Bahar, J.D., M.A., CLP Chief, Cancer Branch Office of Technology Transfer National Institutes of Health U.S. Department.
Like.com vs. Ugmode Prosecution history of patent *** CONFIDENTIAL *** Prepared by Ugmode, Inc.
1 LAW DIVISION PATENT DIVISION TRADEMARK & DESIGN DIVISION ACCOUNTING & AUDITING DIVISION YUASA AND HARA LAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING.
U.S. Patent and Trademark Office Technology Center 1600 Michael P. Woodward Unity of Invention: Biotech Examples.
Harnisch, Unity of Invention, and 76 Fed. Reg AIPLA Biotechnology Committee Presentation March 17, 2011 Brian Lathrop, Ph.D., Esq.
Overcoming Prior Art References Non-Enabling Prior Art References Gary Kunz SPE Art Unit 1616.
1 Restriction Practice Updates Julie Burke TC1600 Quality Assurance Specialist
35 U.S.C. 112, Second Paragraph Examination Memorandum Robert Clarke Director, Office of Patent Legal Administration United States Patent and Trademark.
July 18, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December 10,
Election of Species Joseph K. McKane SPE, Art Unit 1626 April 27, 2004.
Biotech Customer Partnership August 3, 2004 Jasemine C. Chambers, Ph.D., J.D. Director Technology Center 1600 USPTO (571)
1 When is it NOT Appropriate to Restrict? Julie Burke TC1600 QAS
Claims and Continuations Final Rule Overview Briefing for Examiners 1.
Revisions to Japanese Patent Law Before the law was revised, a Divisional Applications could not be filed after a Notice of Allowance 2.
1 Demystifying the Examination of Stem Cell-Related Inventions Remy Yucel, Ph.D. Supervisory Patent Examiner Technology Center 1600 United States Patent.
Claims and Continuations Final Rule 1 Joni Y. Chang Senior Legal Advisor Office of Patent Legal Administration (571) ,
FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice Julie Burke TC1600 Quality Assurance Specialist
Restriction Practice for Combinations and Subcombinations
1 Restriction Petition Survey; A Few Helpful Hints Julie Burke TC1600 Special Program Examiner
James Toupin – General Counsel February 1, Summary of Proposed Rule Changes to Continuations, Double Patenting, and Claims.
Claims Proposed Rulemaking Main Purposes É Applicant Assistance to Improve Focus of Examination n Narrow scope of initial examination so the examiner is.
1 Enablement Issues in Pharmaceutical Claims Joseph K. M c Kane Supervisory Patent Examiner Art Unit Ardin Marschel Supervisory Patent.
Margaret Polson Polson Intellectual Property Law, PC US Design Patents Overview.
Reviewing Common Themes in Double Patenting James Wilson, SPE 1624 TC
Derivation Proceedings Gene Quinn Patent Attorney IPWatchdog.com March 27 th, 2012.
January 25, Notice of Proposed Rule Making Proposed Changes to Practice for Continuing Applications, Requests for Continued Examination Practice,
Double Patenting Deborah Reynolds SPE Art Unit 1632 Detailee, TC1600 Practice Specialist
1 Biotech/Chem/Pharm Customer Partnership Meeting June 15, 2005 USPTO Study on Restriction Reform and Update on TC1600 Restriction Practice Action Plan.
Bruce Kisliuk Group Director, Technology Center 1600.
(c) 2004, David Schnapf, Sheppard Mullin Richter & Hampton LLP 1 Examiner Use of Background Statements David Schnapf Sheppard Mullin Richter & Hampton.
1 FY08 Restriction Petition Update and Burden Julie Burke Quality Assurance Specialist Technology Center 1600.
LYDON - TERMINAL DISCLAIMERS1 Terminal Disclaimer (TD) A Terminal Disclaimer states that the patent –will expire on the same date as a related.
10/13/081 PARK - SPEC SAME IN APP & PAT The Specification: Application v. Issued Patent Why is the specification in the application almost exactly identical.
Tim Saulsbury -- Continuations in Part
Processes Which Employ Non-Obvious Products
Claims and Continuations Final Rule
Ram R. Shukla, Ph.D. SPE AU 1632 & 1634 Technology Center
Presentation transcript:

To Restrict or Not To Restrict That Is The Question? Divided We Stand! Or Undivided We Stand!! By Joseph K. McKane SPE, Art Unit 1626

Restriction Common Goals Quality Examination Consistent Practice Timely Processing There is a great tool to accomplish these where claims have multiple distinct inventions and are burdensome to examine! Can you guess what it is? Hint: The answer is on the top of the slide.

Restriction Brief Background 1952 Patent Act: 35 USC 121 Discretionary authority - Director “may” require restriction Nonelected inventions must be patentably distinct from the elected invention (37 CFR 1.141) Examination of an application to one of a plurality of patentably distinct inventions that would impose a serious burden on the examiner (MPEP 803) In re Joyce, 1958 C.D. 2 (1957) In re Herrick, 1958 C.D. 1 (1957)

Restriction 35 USC 121 and species Patentably Distinct Species – when there are patentably distinct species, there can be an “election of species” to which the application would be limited in the absence of an allowable generic claim (MPEP (a)-(i)); (37 CFR 1.141) A reasonable number of species may be claimed in one application (37 CFR 1.141) When inventions are both (i) species under a claimed genus and (ii) related, then restriction must be determined by the practice applicable to election of species and the practice applicable to other types of restrictions such as those presented in MPEP (i)

Restriction (Markush Practice) Markush Claim - Eugene A. Markush Ex parte Markush, 1925 C.D. 126 Claimed a definition of a genus having a “material selected from the group consisting of aniline, homologues of aniline and halogen substitute of aniline Eventually the Markush-type claim turned into claiming a type of core molecule which may include a megamolecule with various “R” groups, variables and functional groups attached to the core or molecule

Restriction (Markush Practice) The Patent Office must examine what applicants regard as their invention. In re Haas, 486 F.2d 1053, 179 USPQ 623 (CCPA 1973) In re Haas, 580 F.2d 461, 198 USPQ 334 (CCPA 1978) In re Weber, 580 F.2d 455, 198 USPQ 328 (CCPA 1978)

Restriction (Markush Practice) Since the decisions of In re Weber (CCPA 1978) and In re Haas (CCPA 1978): It is improper for the Patent Office to refuse to examine that which applicants regard as their invention, unless the subject matter in a claim lacks unity of invention as defined by: In re Harnisch, 631 F.2d 716, 206 USPQ 300 (CCPA 1980) Ex parte Hozumi, 3 USPQ 2d 1059 (BPAI 1984)

Restriction (Markush Practice) Markush Language – Ex. “selected from the group consisting of…” or “any of A, B, or C”. Apply In re Harnisch test for “unity of invention” Common utility Common structural feature disclosed to be essential to the common utility

Restriction (Markush Practice) Broadly, unity of invention exists where compounds included within a Markush group (1) share a common utility, and (2) share a substantial structural feature disclosed as being essential to that utility.

Restriction (Markush Practice) Markush practice of MPEP 803 applies where unity of invention exists under the Harnisch test Non-markush restriction practice applies where unity of invention does not exist under the Harnisch test

Restriction (Markush Practice) If the members of the Markush group are sufficiently few in number or so closely related that a search and examination of the entire claim can be made without serious burden, the examiner must examine all the members of the Markush group in the claim on the merits, even though they are directed to independent and distinct inventions.

Harnisch Lines Lack of Unity Each slice represents different inventive embodiments Within each slice there are structurally similar groups which passed the Harnisch test

Product/Process Rejoinder MPEP Proper restriction between product and process claims Applies only where product claims are elected Requires allowable product claim Applies only to process claims that depend from or include all the limitations of the allowable product claim

Product/Process Rejoinder If an application discloses both product and process(es) of making and/or using, but claims the product only and a product claim is allowed, process claims may be rejoined prior to final rejection. After final rejection or allowance, amendments will be governed either by 37 CFR or 1.312, respectively.

Product/Process Rejoinder Rejoinder by the Office is sua sponte Less than all pending process claims may be rejoined where less than all process claims depend from or otherwise include all the limitations of the allowable product Obviousness-type double patenting may be applied where product and process claims are voluntarily filed in separate applications

Take Home Message - Restriction Technology Center 1600 is striving to have 1) quality examination, 2) a consistent practice and 3) timely processing. Every examiner in the Technology Center will be receiving restriction practice training during Fiscal Year 04 to achieve the above goals.

Thank You Happy Halloween!